1
|
Boutary S, Echaniz-Laguna A, Adams D, Loisel-Duwattez J, Schumacher M, Massaad C, Massaad-Massade L. Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: the past, the present and the future. Transl Res 2021; 227:100-111. [PMID: 32693030 DOI: 10.1016/j.trsl.2020.07.006] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 07/02/2020] [Accepted: 07/15/2020] [Indexed: 12/30/2022]
Abstract
Charcot-Marie-Tooth (CMT) disease is the most frequent inherited neuropathy, affecting 1/1500 to 1/10000. CMT1A represents 60%-70% of all CMT and is caused by a duplication on chromosome 17p11.2 leading to an overexpression of the Peripheral Myelin Protein 22 (PMP22). PMP22 gene is under tight regulation and small changes in its expression influences myelination and affect motor and sensory functions. To date, CMT1A treatment is symptomatic and classic pharmacological options have been disappointing. Here, we review the past, present, and future treatment options for CMT1A, with a special emphasis on the highly promising potential of PMP22-targeted small interfering RNA and antisense oligonucleotides.
Collapse
Affiliation(s)
- Suzan Boutary
- U 1195, INSERM and Paris-Saclay University, Le Kremlin-Bicêtre, France
| | - Andoni Echaniz-Laguna
- U 1195, INSERM and Paris-Saclay University, Le Kremlin-Bicêtre, France; Neurology Department, AP-HP, Paris-Saclay Universityand French Referent Center for Familial Amyloid Polyneuropathy and Other Rare Peripheral Neuropathies (CRMR-NNERF), Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - David Adams
- U 1195, INSERM and Paris-Saclay University, Le Kremlin-Bicêtre, France; Neurology Department, AP-HP, Paris-Saclay Universityand French Referent Center for Familial Amyloid Polyneuropathy and Other Rare Peripheral Neuropathies (CRMR-NNERF), Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Julien Loisel-Duwattez
- U 1195, INSERM and Paris-Saclay University, Le Kremlin-Bicêtre, France; Neurology Department, AP-HP, Paris-Saclay Universityand French Referent Center for Familial Amyloid Polyneuropathy and Other Rare Peripheral Neuropathies (CRMR-NNERF), Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | | | - Charbel Massaad
- Faculty of Basic and Biomedical Sciences, Paris Descartes University, INSERM UMRS 1124, Paris, France
| | | |
Collapse
|
2
|
Parker WH, Rhea EM, Qu ZC, Hecker MR, May JM. Intracellular ascorbate tightens the endothelial permeability barrier through Epac1 and the tubulin cytoskeleton. Am J Physiol Cell Physiol 2016; 311:C652-C662. [PMID: 27605450 DOI: 10.1152/ajpcell.00076.2016] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Accepted: 08/21/2016] [Indexed: 12/28/2022]
Abstract
Vitamin C, or ascorbic acid, both tightens the endothelial permeability barrier in basal cells and also prevents barrier leak induced by inflammatory agents. Barrier tightening by ascorbate in basal endothelial cells requires nitric oxide derived from activation of nitric oxide synthase. Although ascorbate did not affect cyclic AMP levels in our previous study, there remains a question of whether it might activate downstream cyclic AMP-dependent pathways. In this work, we found in both primary and immortalized cultured endothelial cells that ascorbate tightened the endothelial permeability barrier by ∼30%. In human umbilical vein endothelial cells, this occurred at what are likely physiologic intracellular ascorbate concentrations. In so doing, ascorbate decreased measures of oxidative stress and also flattened the cells to increase cell-to-cell contact. Inhibition of downstream cyclic AMP-dependent proteins via protein kinase A did not prevent ascorbate from tightening the endothelial permeability barrier, whereas inhibition of Epac1 did block the ascorbate effect. Although Epac1 was required, its mediator Rap1 was not activated. Furthermore, ascorbate acutely stabilized microtubules during depolymerization induced by colchicine and nocodazole. Over several days in culture, ascorbate also increased the amount of stable acetylated α-tubulin. Microtubule stabilization was further suggested by the finding that ascorbate increased the amount of Epac1 bound to α-tubulin. These results suggest that physiologic ascorbate concentrations tighten the endothelial permeability barrier in unstimulated cells by stabilizing microtubules in a manner downstream of cyclic AMP that might be due both to increasing nitric oxide availability and to scavenging of reactive oxygen or nitrogen species.
Collapse
Affiliation(s)
- William H Parker
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; and
| | - Elizabeth Meredith Rhea
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Zhi-Chao Qu
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; and
| | - Morgan R Hecker
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; and
| | - James M May
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; and
| |
Collapse
|
3
|
Hosokawa Y, Monzen S, Yoshino H, Terashima S, Nakano M, Toshima K, Saga R, Kashiwakura I. Effects of X‑ray irradiation in combination with ascorbic acid on tumor control. Mol Med Rep 2015; 12:5449-54. [PMID: 26238154 DOI: 10.3892/mmr.2015.4108] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Accepted: 06/17/2015] [Indexed: 11/06/2022] Open
Abstract
Our previous studies demonstrated that the combination of treatment with ascorbic acid (AsA) and X‑ray irradiation results in increased apoptosis in HL60 cells. The present study was performed to investigate the effects of the combined use of AsA and X‑ray irradiation on epithelial cancer and sarcoma cells, and its potential use in future clinical treatment. X‑ray irradiation combined with AsA treatment resulted in increased suppression of cell growth of HT1080, SAS and A549 cells in vitro compared with X‑ray irradiation alone. The combined treatment also suppressed tumor growth in implanted HT‑1080 cells in vivo. Using annexin V/propidium iodide staining and the detection of activated caspase 3, it was found that X‑ray irradiation increased the apoptotic rate of HT1080 cells and resulted in G2/M arrest. However, apoptosis in the HT1080 cells treated with 5 mM AsA remained unchanged, and no changes were observed in the G2/M fraction. By contrast, AsA treatment caused increased suppression of proliferation compared with X‑ray irradiation. These results suggested that 5 mM AsA slowed the cell cycle and reduced tumor growth. Therefore, X‑ray irradiation combined with AsA treatment may be effective against epithelial cancer and sarcoma cells.
Collapse
Affiliation(s)
- Yoichiro Hosokawa
- Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
| | - Satoru Monzen
- Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
| | - Hironori Yoshino
- Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
| | - Shingo Terashima
- Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
| | - Manabu Nakano
- Department of Bioscience and Laboratory Medicine, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
| | - Keisuke Toshima
- Department of Radiology, Akita University Hospital, Akita, Akita 010‑8543, Japan
| | - Ryo Saga
- Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
| | - Ikuo Kashiwakura
- Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
| |
Collapse
|
4
|
Parker WH, Qu ZC, May JM. Intracellular Ascorbate Prevents Endothelial Barrier Permeabilization by Thrombin. J Biol Chem 2015; 290:21486-97. [PMID: 26152729 DOI: 10.1074/jbc.m115.662098] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Indexed: 12/11/2022] Open
Abstract
Intracellular ascorbate (vitamin C) has previously been shown to tighten the endothelial barrier and maintain barrier integrity during acute inflammation in vitro. However, the downstream effectors of ascorbate in the regulation of endothelial permeability remain unclear. In this study, we evaluated ascorbate as a mediator of thrombin-induced barrier permeabilization in human umbilical vein endothelial cells and their immortalized hybridoma line, EA.hy926. We found that the vitamin fully prevented increased permeability to the polysaccharide inulin by thrombin in a dose-dependent manner, and it took effect both before and after subjection to thrombin. Thrombin exposure consumed intracellular ascorbate but not the endogenous antioxidant GSH. Likewise, the antioxidants dithiothreitol and tempol did not reverse permeabilization. We identified a novel role for ascorbate in preserving cAMP during thrombin stimulation, resulting in two downstream effects. First, ascorbate maintained the cortical actin cytoskeleton in a Rap1- and Rac1-dependent manner, thus preserving stable adherens junctions between adjacent cells. Second, ascorbate prevented actin polymerization and formation of stress fibers by reducing the activation of RhoA and phosphorylation of myosin light chain. Although ascorbate and thrombin both required calcium for their respective effects, ascorbate did not prevent thrombin permeabilization by obstructing calcium influx. However, preservation of cAMP by ascorbate was found to depend on both the production of nitric oxide by endothelial nitric-oxide synthase, which ascorbate is known to activate, and the subsequent generation cGMP by guanylate cyclase. Together, these data implicate ascorbate in the prevention of inflammatory endothelial barrier permeabilization and explain the underlying signaling mechanism.
Collapse
Affiliation(s)
- William H Parker
- From the Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6303
| | - Zhi-chao Qu
- From the Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6303
| | - James M May
- From the Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6303
| |
Collapse
|
5
|
Rahman F, Al Frouh F, Bordignon B, Fraterno M, Landrier JF, Peiretti F, Fontes M. Ascorbic acid is a dose-dependent inhibitor of adipocyte differentiation, probably by reducing cAMP pool. Front Cell Dev Biol 2014; 2:29. [PMID: 25364736 PMCID: PMC4207035 DOI: 10.3389/fcell.2014.00029] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Accepted: 06/29/2014] [Indexed: 12/14/2022] Open
Abstract
Ascorbic acid (AA) is the active component of vitamin C and antioxidant activity was long considered to be the primary molecular mechanism underlying the physiological actions of AA. We recently demonstrated that AA is a competitive inhibitor of adenylate cyclase, acting as a global regulator of intracellular cyclic adenosine monophosphate (cAMP) levels. Our study, therefore, aimed to determine new targets of AA that would account for its potential effect on signal transduction, particularly during cell differentiation. We demonstrated that AA is an inhibitor of pre-adipocyte cell line differentiation, with a dose-dependent effect. Additionally, we describe the impact of AA on the expression of genes involved in adipogenesis and/or the adipocyte phenotype. Moreover, our data suggest that treatment with AA partially reverses lipid accumulation in mature adipocytes. These properties likely reflect the function of AA as a global regulator of the cAMP pool, since an analog of AA without any antioxidant properties elicited the same effect. Additionally, we demonstrated that AA inhibits adipogenesis in OP9 mesenchymal cell line and drives the differentiation of this line toward osteogenesis. Finally, our data suggest that the intracellular transporter SVCT2 is involved in these processes and may act as a receptor for AA.
Collapse
Affiliation(s)
- Fryad Rahman
- Nutrition, Obesity and Risk of Thrombosis, INSERM U 1062, INRA 1260, Aix-Marseille University Marseille, France
| | - Fadi Al Frouh
- Nutrition, Obesity and Risk of Thrombosis, INSERM U 1062, INRA 1260, Aix-Marseille University Marseille, France
| | - Benoit Bordignon
- Nutrition, Obesity and Risk of Thrombosis, INSERM U 1062, INRA 1260, Aix-Marseille University Marseille, France
| | - Marc Fraterno
- Service of Electron Microscope, Faculté de Médecine, Aix-Marseille University Marseille, France
| | - Jean-François Landrier
- Nutrition, Obesity and Risk of Thrombosis, INSERM U 1062, INRA 1260, Aix-Marseille University Marseille, France
| | - Franck Peiretti
- Nutrition, Obesity and Risk of Thrombosis, INSERM U 1062, INRA 1260, Aix-Marseille University Marseille, France
| | - Michel Fontes
- Nutrition, Obesity and Risk of Thrombosis, INSERM U 1062, INRA 1260, Aix-Marseille University Marseille, France
| |
Collapse
|
6
|
Mones S, Bordignon B, Peiretti F, Landrier JF, Gess B, Bourguignon JJ, Bihel F, Fontés M. CamKII inhibitors reduce mitotic instability, connexon anomalies and progression of the in vivo behavioral phenotype in transgenic animals expressing a mutated Gjb1 gene. Front Neurosci 2014; 8:151. [PMID: 24982612 PMCID: PMC4056282 DOI: 10.3389/fnins.2014.00151] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2014] [Accepted: 05/24/2014] [Indexed: 11/30/2022] Open
Abstract
Mutation in the Gjb1 gene, coding for a connexin (Cx32), is associated with an inherited peripheral neuropathic disorder (X-linked Charcot-Marie-Tooth, CMTX). Our previous work reported that transgenic animals expressing a human Gjb1 transgene present polyploidy and abnormal over-duplication of the centrosome, suggesting a role for Gjb1 in mitotic stability. In this article, we propose mechanisms by which mutations in Gjb1 induce mitotic instability and discuss its potential relation with the CMTX phenotype. We showed that transgenic cells exhibit CamKII over-stimulation, a phenomenon that has been linked to mitotic instability (polyploidy, nuclear volume and centrosome over-duplication), that is reversed by CamKII inhibitors. We also demonstrate that connexon activity is partially restored in transgenic cells with CamKII inhibitors. Our model supports the role for Pim1, a kinase that has been associated with genomic instability in cancers, in genomic instability in Cx32 mutations. Regarding in vivo phenotype, we showed that degradation on the rotarod test in our transgenic mice is significantly lowered by treatment with a CamKII inhibitor (KN93). This effect was seen in two lines with different point mutations in GJB1, and stopping the treatment led to degradation of the phenotype.
Collapse
Affiliation(s)
- Saleh Mones
- Therapy of Genetic Disorders, Faculté de Médecine, EA 4263, Aix-Marseille Université Marseille, France ; INSERM, UMR1062, Nutrition, Obesity and Risk of Thrombosis, Faculté de Médecine Marseille, France ; INRA, UMR1260, Faculté de Médecine Marseille, France
| | - Benoit Bordignon
- Therapy of Genetic Disorders, Faculté de Médecine, EA 4263, Aix-Marseille Université Marseille, France ; INSERM, UMR1062, Nutrition, Obesity and Risk of Thrombosis, Faculté de Médecine Marseille, France ; INRA, UMR1260, Faculté de Médecine Marseille, France
| | - Franck Peiretti
- INSERM, UMR1062, Nutrition, Obesity and Risk of Thrombosis, Faculté de Médecine Marseille, France ; INRA, UMR1260, Faculté de Médecine Marseille, France
| | - Jean F Landrier
- INSERM, UMR1062, Nutrition, Obesity and Risk of Thrombosis, Faculté de Médecine Marseille, France ; INRA, UMR1260, Faculté de Médecine Marseille, France
| | - Burkhardt Gess
- Department of Sleep Medicine and Neuromuscular Disorders, University Hospital Münster Münster, Germany
| | - Jean J Bourguignon
- Laboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, CNRS, UMR7200, Université de Strasbourg Illkirch Graffenstaden, France
| | - Frédéric Bihel
- Laboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, CNRS, UMR7200, Université de Strasbourg Illkirch Graffenstaden, France
| | - Michel Fontés
- Therapy of Genetic Disorders, Faculté de Médecine, EA 4263, Aix-Marseille Université Marseille, France ; INSERM, UMR1062, Nutrition, Obesity and Risk of Thrombosis, Faculté de Médecine Marseille, France ; INRA, UMR1260, Faculté de Médecine Marseille, France
| |
Collapse
|